VivoSeq
Cardiovascular

Hypertrophic Cardiomyopathy

47

Pipeline Programs↗

31

Active Trials↗

20

Companies Involved↗

Hypertrophic Cardiomyopathy is a moderately active landscape with 47 programs across 20 companies. The most active players are Imbria Pharmaceuticals, Inc., Edgewise Therapeutics, Inc., Corxel Pharmaceuticals. 15 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

30/100

Mech. Concentration

15/100

Completion Rate

76/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Imbria Pharmaceuticals, Inc.

2 programs

Phase 2E

Edgewise Therapeutics, Inc.

1 program

Phase 2C

Corxel Pharmaceuticals

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2L

Lexicon Pharmaceuticals

1 program

Phase 3Gilead logo

Gilead

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

70

clinical trials

Completed26 · 37%
Recruiting18 · 26%
Active, not recruiting10 · 14%
Terminated5 · 7%
Unknown status5 · 7%
Withdrawn3 · 4%
Other3 · 4%

Clinical Trials

Trial Activity

70 trials

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT05489705·1,600 enrolled
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
Recruiting·MMedical University of Vienna·N/A·NCT07150299·20 enrolled
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
Recruiting·MMedical University of Warsaw·Phase 2·NCT06555237·40 enrolled
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Recruiting·CCytokinetics·Phase 2/3·NCT06412666·55 enrolled
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT06816251·84 enrolled
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT07361289·500 enrolled
ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
Recruiting·YYonsei University·Phase 4·NCT06580717·200 enrolled
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
Recruiting·CChina National Center for Cardiovascular Diseases·Phase 2·NCT07367724·44 enrolled
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT07383025·200 enrolled
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 3·NCT07021976·216 enrolled
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT06146660·600 enrolled
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Recruiting·IImbria Pharmaceuticals, Inc.·Phase 2·NCT07023614·165 enrolled
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
Recruiting·MMorten Steen Kvistholm Jensen·Phase 4·NCT05569382·100 enrolled
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
Recruiting·UUniversity of Pennsylvania·Phase 1·NCT06433050·26 enrolled
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Recruiting·LLexicon Pharmaceuticals·Phase 3·NCT06481891·500 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)